5:32PM Idenix Pharma reported data for IDX899; IDX899; demonstrates rapid and profound inhibition of HIV replication in a Phase I/II Clinical Trial (IDIX) 4.94 -0.06 : Co reported data for IDX899, a non-nucleoside reverse transcriptase inhibitor being developed for the treatment of HIV. In the first dosing cohort of an ongoing phase I/II study, eight HIV-1 infected treatment-naive patients receiving 800 mg of IDX899 once-daily achieved a mean reduction in virus level of 2.01 log(10), or 99%, after seven days of treatment. Additionally, two posters detailing the in-vitro resistance and pharmacokinetic profile in man of IDX899 were presented at the 2008 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Boston, MA.
Market Data 
Markets 
AI
